The market for Europe hereditary genetic testing is predicted to grow at a CAGR of 13.34% during the forecast period 2021-2031 – Yahoo Finance
Posted: November 7, 2021 at 1:03 am
Europe Hereditary Genetic Testing Market to Reach $19. 31 Billion by 2031. Market Report Coverage - Europe Hereditary Genetic Testing Market Segmentation.
New York, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Europe Hereditary Genetic Testing Market - A Regional Analysis: Focus on Products, Sample Type, Applications, and Nordic and Baltic Region, Country Data (12 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2031" - https://www.reportlinker.com/p06178588/?utm_source=GNW
Product Kits, Consumables, Services, Others Sample Type Tumor Tissue, Bone Marrow, Blood, Saliva, Others Application Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, Prenatal Screening and Preimplantation Testing, Rare Disease Testing, Direct-to-Consumer (DTC) Testing
Regional Segmentation
EU5: Germany, U.K., France, Italy, Spain Nordic Region: Finland, Sweden, Denmark, Norway Baltic Region: Estonia, Lithuania, Latvia
Market Growth Drivers
Increasing Awareness Toward Hereditary Genetic Testing Rising Prevalence of Genetic Disorders Increasing Research Funding in the Field of Genomics
Market Challenges
High Cost of Genetic Testing Stringent Regulatory Standards
Market Opportunities
Technological Advancements in the Hereditary Genetic Testing Process Growing Demand for Direct-to-Consumer (DTC) Testing Service
Key Companies Profiled
Agilent Technologies, Inc., Woble Helsinki Oy, Negen Oy, Devyser, CeGat GmbH, Beijing Genomics Institute (BGI), BerGenBio ASA, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Illumina, Inc., Myriad Genetics, Inc., Alnylam Pharmaceuticals, Inc., Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc.
Key Questions Answered in this Report: What is the current trend in the Europe hereditary genetic testing market? Based on products, which segment is anticipated to witness a massive rise in demand during the forecast period 2021-2031? Based on sample type, which segment is anticipated to witness a massive rise in demand during the forecast period 2021-2031? Based on types of testing, which segment is anticipated to witness a massive rise in demand during the forecast period 2021-2031? Based on countries, which country is anticipated to witness a massive rise in demand during the forecast period 2021-2031? What are the major drivers, challenges, and opportunities in the Europe hereditary genetic testing market? What are the key developmental strategies implemented by the key players to stand out in this market? Which leading companies are dominating the Europe hereditary genetic testing market, and what is the share of these companies in the Europe hereditary genetic testing market? What are the regulations pertaining to the Europe hereditary genetic testing market, and what initiatives have been implemented by different government bodies regulating the development and commercialization of Europe hereditary genetic testing? How is each segment of the Europe hereditary genetic testing market expected to grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2031? How is the market for Europe hereditary genetic testing expected to evolve during the forecast period 2021-2031? What is the market scenario for the Europe hereditary genetic testing market in different countries? What are the key trends of different regions in the Europe hereditary genetic testing market? Which country is expected to contribute to the highest sales in the Europe hereditary genetic testing market during the forecast period 2021-2031?
Market Overview
Genetic testing is a type of DNA testing used to determine changes in chromosome structure or DNA sequence.Genetic testing can also include measuring the outcomes of genetic modifications, such as mutation, RNA analysis as an output of gene expression, or biochemical analysis to measure specific protein output.
For cancer risk, genetic testing includes testing for inherited genetic variants that can be associated with a high to moderately increased risk of cancer in the patient and are responsible for inherited cancer susceptibility syndromes.
Hereditary genetic testing classifies changes in chromosomes, genes, and proteins.The outcome of hereditary genetic testing authorizes a suspected genetic condition that further helps to determine a persons chance of passing or developing a genetic disorder.
To date, more than 1,000 hereditary genetic tests have been used, and many others are being developed for testing.
Europe is one of the powerhouses for genomic science and research.Genetic testing data sharing is becoming an integral part as scientists join forces across borders for enabling genetic testing for the benefit of mankind.
Genetic testing can be performed for various purposes, which may or may not fall in medical science.Thus, regulatory needs depend on the context of the test being performed and for which purpose.
It can be either to detect monogenic diseases, medical-nonmedical purposes, predispositions or carrier tests, diagnostic and treatment purposes, predictive tests for late-onset diseases, drug response, family planning, forensics, population screening, and DNA profiling or research.
With several companies eagerly competing to establish dominance in the Europe hereditary genetic testing market, several emerging companies have undertaken significant activities to establish their position in the market. Although these companies are currently far behind the market leaders, some of them have made significant strides to grow into major players, owing to initiatives undertaken to expand their respective product portfolios and regional footprints.
BIS healthcare experts have found hereditary genetic testing to be one of the most rapidly evolving markets. The market for Europe hereditary genetic testing is predicted to grow at a CAGR of 13.34% during the forecast period 2021-2031. As per BIS research, hereditary genetic testing comprises the ecosystem of multiple services offered, products used, and the target population.
The optimistic scenario of the market can be witnessed if the COVID-19 recovery is swift across key countries in Europe.The scenario assumes an increasing demand for technology, products, services, and growth in the end-user base across regions.
Furthermore, the scenario also assumes more product and service launches for genetic testing, especially in the Nordic and Baltic regions. Additionally, the companies in the market are investing more in rare disease and reproductive genetics, which is one of the bolstering factors for optimistic growth.
The following report presents the reader with an opportunity to unlock comprehensive insights with respect to the Europe hereditary genetic testing market and helps in forming well-informed strategic decisions. The market research study also offers a wide perspective of the different types of hereditary genetic testing products and services available in the market and their impact on the diagnostic and genomics industry by providing critical insights into the direction of its future expansion.
The Europe hereditary genetic testing market has been growing since its inception. Several European countries, including Germany, France, the U.K., Italy, Spain, Denmark, Finland, Sweden, Norway, Estonia, Lithuania, and Latvia, are working persistently to enhance the adoption of precision medicine solutions, including hereditary genetic testing market, across Europe region. Acknowledging the unique role of hereditary genetic testing is a significant step toward the establishment of a suitable and effective regulatory approval procedure, coupled with an effective pricing strategy and reimbursement policy. However, country-specific technology evaluation and reimbursement policies in Europe may result in different coverage for many genetic testing technologies across Europe. For instance, in France, Germany, Italy, and the U.K., HER2 testing is publicly funded. However, in Spain, the majority of NGS testing is funded by hereditary-based test manufactures. Therefore, companies are trying to work closely with the payers and other decision-makers to increase the adoption on a country-by-country, and in few cases, hospital-by-hospital basis, which generally limits accessibility and results in a poor adoption rate.
Germany accounted for the maximum share of the market within the Europe region in 2020.The country has one of the biggest pharmaceutical markets in Europe.
Further, it is among the largest exporter of medicinal products and ranks among the top pharmaceutical producers globally.The growth in this region can be primarily attributed to the rising pharmaceutical R&D expenditure, increasing geriatric population coupled with growing disease prevalence, and the rising focus to eradicate rare diseases across the region.
However, the region also faces high competition from the Asian economies that offer cheap manufacturing materials and low cost of labor.
Within the research report, the market is segmented based on products, sample type, applications, and region.Each of these segments has been further categorized into sub-segments to compile an in-depth study.
Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The Europe hereditary genetic testing market is largely dominated by companies such as Woble Helsinki Oy, Negen Oy, Devyser, CeGaT GmbH, Beijing Genomics Institute (BGI), BerGenBio ASA, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Illumina, Inc., Laboratory Corporation of America Holdings, Myriad Genetics, Inc., Alnylam Pharmaceuticals, Inc., Quest Diagnostics Incorporated, and Thermo Fisher Scientific Inc.
Companies such as LabCorp, Illumina, Myriad, and Quest Diagnostics are the leading suppliers of genetic testing products and services in the Europe market.When compared to the other European countries, the Nordic and Baltic region is mainly dominated by Bluprint Genetics (Quest Diagnostics) and Eurofins.
In addition, regional players such as Devyser, CeGat GmbH, and Negen Oy offer products in the markets.
Among the Nordic and Baltic regions, the Nordic region contributes more to the Europe hereditary genetic testing market.The country which performs the largest number of genetic tests in the Nordic region is Finland.
A lot of investment in research for characterization of the population for rare diseases has been made in Finland by Blueprint Genetics.
Countries Covered EU5 Germany U.K. France Italy Spain Nordic Region Finland Sweden Denmark Norway Baltic Region Estonia Lithuania LatviaRead the full report: https://www.reportlinker.com/p06178588/?utm_source=GNW
About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Story continues
Go here to read the rest:
The market for Europe hereditary genetic testing is predicted to grow at a CAGR of 13.34% during the forecast period 2021-2031 - Yahoo Finance
- Alzheimer's and Genetic Testing: Your Questions Answered - Healthline - March 12th, 2024
- The Evolving Treatment Landscape in EGFR Mutated NSCLC and the Role of Comprehensive Genetic Testing in ... - Cancer Network - March 4th, 2024
- PART II: The Legalities of Pre-Natal Genetic Testing - American Council on Science and Health - March 4th, 2024
- Cord Blood Registry (CBR) by CooperSurgical and Fulgent Genetics Launch Innovative Genetic Testing - PR Newswire - February 13th, 2024
- Australian life insurers support industry ban on use of genetic testing results - Proactive Investors UK - February 5th, 2024
- Predictive genetic testing helps breast cancer patient Tammy Goodsell - East Kent Hospitals University NHS Foundation Trust - February 5th, 2024
- Significance of Early Genetic Testing in HRR-Mutated mCRPC Highlighted by Real-World Observations - Targeted Oncology - January 28th, 2024
- Genetic testing saves lives but can lead to discrimination when it comes to life insurance - ABC News - January 28th, 2024
- Growth of the U.S. DTC Genetic Testing Market | Personalized Nutrition Medicine - Medriva - January 11th, 2024
- Genetic Testing - Mayo Clinic Health System - January 3rd, 2024
- However good genetic testing gets, there will always be plenty of space for you to make a total mess of things entirely of ... - CyclingWeekly - January 3rd, 2024
- Preimplantation Genetic Testing Market is Expected to Reach $1.2 Billion | MarketsandMarkets. - Yahoo Finance - December 25th, 2023
- Prenatal and Newborn Genetic Testing Market Size to Hit Eyes USD 14.72 billion by 2031 | CAGR Of 11. - PharmiWeb.com - December 16th, 2023
- Hereditary Genetic Testing Market Study on Investment Possibilities, Industry Share, and Trends through 2030 - EIN News - May 5th, 2023
- Genetic Testing: What You Should Know - Healthline - April 18th, 2023
- Genetic Testing: How It Works, Types, and Diagnosis | Patient - April 18th, 2023
- Genetic Testing Fact Sheet - NCI - National Cancer Institute - March 31st, 2023
- Tempted to have genetic testing? First ask why - Harvard Health - March 31st, 2023
- DNA Test - Genetic Testing Overview - Cleveland Clinic - February 10th, 2023
- Genetic Disorders: What Are They, Types, Symptoms & Causes - January 25th, 2023
- The Genetics of Cancer - NCI - January 25th, 2023
- Understanding Genetic Testing for Cancer Risk - December 28th, 2022
- Prenatal Genetic Diagnostic Tests | ACOG - December 28th, 2022
- DiGeorge Syndrome - StatPearls - NCBI Bookshelf - December 28th, 2022
- Global Rare Disease Genetic Testing Market Report 2022: Ongoing Conferences to Raise Awareness About Rare and Ultra-Rare Conditions to Boost Growth -... - September 21st, 2022
- Genome Medical and Pierian Announce Collaboration to Optimize Genomic Testing Programs - Business Wire - September 21st, 2022
- DNAfit Review: What It Can and Can't Tell You - Healthline - September 21st, 2022
- Purrsonalised health: The startups and VCs betting on pet genetics - Sifted - September 21st, 2022
- One of my daughters and I have the BRCA1 gene mutation - Insider - September 21st, 2022
- Lab testing transparency will improve patient care and lower costs - MedCity News - September 21st, 2022
- Artificial Intelligence Tool May Help in Early Diagnosis of... - Fragile X News Today - September 21st, 2022
- Feral swine meetings Thursday in Eureka and Libby - The Western News - September 21st, 2022
- Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer - Cancer Network - September 21st, 2022
- Australia moves to future in biotech and medical technologies with billions in new investment - The New Daily - September 21st, 2022
- Ticking away in the back of my mind: what does it mean to know the risk embedded in your DNA? - The Guardian - September 5th, 2022
- Ambry Genetics Publishes 43,000 Patient Study Showing Combined RNA and DNA Analysis Identifies Patients Who Are High-Risk for Cancer but Would Have... - September 5th, 2022
- Genetic Mosaicism Diagnosed in Case of Atypical Angelman Teen |... - Angelman Syndrome News - September 5th, 2022
- Patients and Parents Impacted by SMA May Be Optimistic About Prenatal Testing, Therapies - AJMC.com Managed Markets Network - September 5th, 2022
- Major Depression: The Chemical Imbalance Pillar Is CrumblingIs the Genetics Pillar Next? - Mad In America - Mad in America - September 5th, 2022
- MedGenome Raises $50M To Map The Human Genome - Crunchbase News - September 5th, 2022
- IVF or IUI: Which one to choose for a fertility treatment? - Health shots - September 5th, 2022
- Global Molecular Diagnostics Market is projected to grow at a CAGR of 7.28% by 2032: Visiongain Reports Ltd - Yahoo Finance - September 5th, 2022
- Overview and Prevalence of Dravet Syndrome - Contemporary Pediatrics - September 5th, 2022
- 'It takes toughness and grit' Beasley shares on her breast cancer battle, survivor's journey - Cody Enterprise - September 5th, 2022
- Warning to pregnant Norwegian women as their DNA can be accessed by Chinese authorities - ScandAsia.com - September 5th, 2022
- Global Molecular Diagnostics Devices and Equipment Market Report 2022: A $46.87 Billion Market in 2026 - Long-term Forecast to 2031 -... - September 5th, 2022
- Hereditary Prostate Cancer Genetic Testing: Motivation & Family Communication - Physician's Weekly - August 20th, 2022
- Restrictive abortion laws are limiting the options parents have after receiving genetic test results, experts say - Yahoo Philippines News - August 20th, 2022
- Conversations with a friend on IVF genetic testing - Malta Independent Online - August 20th, 2022
- How a simple home DNA test unravelled the genetic code that could help prolong my life - The National - August 20th, 2022
- 5 Health Issues That are Genetically Passed Down. Do You Have One? Eat This Not That - Eat This, Not That - August 20th, 2022
- 25 Years After 'Gattaca' Released, What Do Genetic Scientists Think About It? The Wire Science - The Wire Science - August 20th, 2022
- A lasting inheritance: City of Hope replaced my family's fear with hope - City of Hope - August 20th, 2022
- Statistics on Global Esoteric Testing Market Size & Share to Surpass USD 37917.67 Million by 2028, Exhibit a CAGR of 11.10% | Industry Trends,... - August 20th, 2022
- Population Genetic Testing: Save Lives And Money, While Avoiding Financial Toxicity - Forbes - August 11th, 2022
- Care before carrying: The significant role of Preimplantation Genetic Testing during IVF - Times of India - August 11th, 2022
- More on Professor Sarnoff's Perspective on Tillis Patent Eligibility Bill - JD Supra - August 11th, 2022
- The Silver Lining Of Innovation in Genetic Medicine - Pharmaceutical Executive - August 11th, 2022
- High susceptibility of animal-borne disease transmission to humans has pushed the animal genetics market to surpass ~ US$ 8 Billion by 2026 - BioSpace - August 11th, 2022
- Fulgent Genetics Announces Launch of PCR Based Test to Detect Monkeypox - Business Wire - August 11th, 2022
- INVITAE CORP 10-Q Management's Discussion and Analysis of Financial Condition and Results of Operations - Insurance News Net - August 11th, 2022
- U.P. man found guilty of poaching multiple 8-point deer ordered to pay $18K in restitution - MLive.com - August 11th, 2022
- Testing, Inspection, And Certification Market Worth $491.3 Billion by 2030: Grand View Research, Inc. - PR Newswire - August 11th, 2022
- BRCA Gene Mutation Can Be Passed Down From Father's Side - SurvivorNet - August 11th, 2022
- The Worldwide Genetic Testing Industry is Expected to Reach $26 Billion by 2027 - ResearchAndMarkets.com - Galveston County Daily News - July 26th, 2022
- Genetic testing may benefit patients with depression - VAntage Point - VAntage Point Blog - July 26th, 2022
- What Does it Mean to be High Risk for Breast Cancer? - Integris - July 26th, 2022
- Boy has rare genetic disease, life expectancy is five to 10 years - Insider - July 26th, 2022
- Preimplantation Genetic Testing Market Research | Industry Growing with Major Key Player Illumina, Inc (U.S.), SciGene Corporation (U.S.), Thermo... - July 26th, 2022
- Direct-To-Consumer (DTC) Genetic Testing Market Size, Scope, Growth Opportunities, Trends by Manufacturers And Forecast to 2029 This Is Ardee - This... - July 26th, 2022
- World IVF Day: 4 benefits of IVF treatment at the right age - Health shots - July 26th, 2022
- Global Metabolic Panel Testing Market to Grow with a CAGR of ~7% During 2022-2031; Market Growth to be Propelled by Increasing Prevalence of Chronic... - July 26th, 2022
- 3 Reasons to Buy This Sizzling Growth Stock - The Motley Fool - July 26th, 2022
- Monkeypox, yet another health emergency for world to cope with - China Daily - July 26th, 2022
- Rhinostics Launches the VERIstic to Redefine Small Volume Blood Collection - BioSpace - July 26th, 2022
- Direct-To-Consumer (DTC) Genetic Testing Market Size, Forecast And Trend Analysis To 2028 This Is Ardee - This Is Ardee - July 26th, 2022
- PSS: Providing quick and effective solutions - The Worldfolio - July 26th, 2022
- Prevencio Announces Agreement with Alivio Health Expanding Access to AI-Driven Cardiac HART Tests Offered by Atlas Genomics - Business Wire - July 26th, 2022
- Myriad Genetics Teams Up with Epic to Make Genetic Testing Accessible to More Patients with Electronic Health Record (EHR) Integration - GlobeNewswire - June 28th, 2022
- Global Predictive Genetic Testing And Consumer/Wellness Genomics Market Emerging Scope Of The 2022 | Illumina, BGI, Genesis Genetics, Myriad Genetics ... - June 28th, 2022